Climb Bio, Inc. CLYM
11.66
(0.23)
(1.93%)
as of 25 Sep
- Market cap
- $682.9M
- P/E
- 0.0×
Follow CLYM
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
— | 27.18 | 7.18 | 24.58 | 22.04 | 38.92 | 31.41 | 15.16 |
Net Debt/EBITDA |
— | 2.85 | 0.98 | 3.87 | 2.73 | 2.51 | 1.82 | 1.44 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.68 | 0.61 | 0.69 | 0.83 | 0.59 | 0.21 | 0.91 |
Capex/Depreciation |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 48.39% | 150.29% | (73.17%) | (30.58%) | (29.72%) | (46.26%) | (32.15%) | |
| — | (69.09%) | (99.74%) | (52.59%) | (29.36%) | (28.61%) | (45.11%) | (31.10%) | |
ROIC |
— | 0.00% | 0.00% | (72.57%) | (547.86%) | (3,142.56%) | (84.09%) | (71.43%) |
Return on Tangible Assets |
— | (36.05%) | (121.22%) | (36.58%) | (35.14%) | (32.69%) | (49.22%) | (60.36%) |
Average Days of Receivables |
— | — | — | — | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) |
Cash per Share |
— | 0.81 | 9.36 | 11.13 | 4.70 | 3.96 | 3.13 | 1.49 |
Shareholders Equity per Share |
— | 0.78 | (11.42) | 13.64 | 4.89 | 3.99 | 4.40 | 2.37 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.78 | (11.42) | 13.64 | 4.89 | 3.99 | 4.40 | 2.37 |
Free Cash Flow |
— | (5.01) | (14.10) | (36.07) | (37.37) | (20.60) | (15.56) | (54.54) |
Working Capital |
— | 20.50 | 18.94 | 142.22 | 128.30 | 107.42 | 149.94 | 98.87 |
Capital Expenditures |
— | — | — | — | — | — | — | (0.19) |
Net Current Asset Value |
— | 20.50 | (27.62) | 142.21 | 128.12 | 107.39 | 149.57 | 98.58 |
| Other line items | ||||||||
Quick Ratio |
— | 27.10 | 6.69 | 22.63 | 20.27 | 37.70 | 30.61 | 14.47 |
Depreciation/Fixed assets |
— | — | — | 0.00 | (0.38) | 0.00 | (3.80) | (7.56) |
Cash ROIC |
— | (11.97%) | 313.57% | (11.88%) | (15.00%) | (9.61%) | (4.34%) | (20.89%) |
Accounts Payable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.19) | (6.44) | (2.94) | (1.42) | (0.76) | (0.32) | (0.80) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | — | 1.35 | 1.35 | 1.08 | 0.41 | 0.39 | 1.49 |
Average Assets |
— | 10.70 | 23.01 | 98.94 | 154.12 | 122.73 | 163.83 | 192.47 |
Average Common Equity |
— | (15.27) | (15.27) | 71.11 | 147.96 | 118.16 | 159.74 | 186.18 |
Capex to Sales |
— | — | — | — | — | — | — | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates